TPX-114
Phase 3Biologic
TPX-114 is one of 28 biologic programs targeting Rotator Cuff Tear. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Rotator Cuff Tear
#DrugCompanyPhaseTrials
1Suboxone
IIndivior Inc.
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Ultram
WWim Janssens
Approved
Valium
Akero TherapeuticsApproved
IC-Green
CCHX Technologies Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Tylenol
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TPX-114. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- TTego Science, Inc.